Equities

Stayble Therapeutics AB

Stayble Therapeutics AB

Actions
  • Price (SEK)0.2495
  • Today's Change0.00 / 0.00%
  • Shares traded49.25k
  • 1 Year change-80.66%
  • Beta-0.1993
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-23.74m
  • Incorporated2015
  • Employees3.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bio Vitos Pharma AB2.98m-12.87m4.11m1.00--1.078.001.38-0.2547-0.25470.05330.11190.09890.005.382,983,990.00-42.63-31.11-44.50-32.92100.00---431.21-1,026.764.27--0.00--126.97--13.64------
European Institute of Science AB686.00k-2.76m5.15m0.00--1.97--7.51-4.23-4.231.051.930.24351.249.46---97.91-93.04-105.11-103.1459.3367.01-402.04-518.825.70--0.00--13.698.540.4062------
QuiaPEG Pharmaceuticals Holding AB0.00-16.52m5.33m8.00--0.3498-----3.51-3.510.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
2cureX AB155.00k-30.82m6.20m----0.4526--39.98-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Lipidor AB77.00k-11.49m6.26m--------81.29-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
XP Chemistries AB663.69k-8.04m6.54m2.00--0.2546--9.85-0.2846-0.28460.02130.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79--0.00---37.14---1.55------
Stayble Therapeutics AB0.00-23.74m7.91m3.00--0.4794-----0.9492-0.94920.000.52040.00----0.00-116.21-78.64-141.76-95.58------------0.049------3.22------
Eurocine Vaccines AB5.00k-15.06m9.44m3.00------1,888.38-0.1472-0.14720.00005-0.00180.0007--0.002---199.76-83.17-323.19-97.89-199,780.00---301,180.00--------------8.95------
Carbiotix AB (publ)1.70m-14.55m9.91m10.00--0.3686--5.83-0.2357-0.23570.01960.14920.0658--3.43170,052.00-56.32-49.38-62.10-55.50201.79574.69-855.62-1,828.86---45.740.00--259.56-12.04-10.02--13.64--
Amniotics AB (publ)0.00-30.87m10.66m6.00--0.6803-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Diagonal Bio AB23.00k-11.68m12.70m4.00--0.0984--552.18-0.1982-0.19820.00040.32210.0007--2.005,750.00-37.35---44.49---41,604.35---50,769.57--0.5105-104.20-----88.67--27.75------
Data as of May 17 2024. Currency figures normalised to Stayble Therapeutics AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.